Gefarnate
- Generic Name
- Gefarnate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H44O2
- CAS Number
- 51-77-4
- Unique Ingredient Identifier
- 1ISE2Y6ULA
- Background
Gefarnate has been investigated for the treatment and prevention of Stomach Ulcer, Duodenal Ulcer, and Cardio-cerebrovascular Disease.
- Indication
1.各种原因引起的胃及十二指肠溃疡、急慢性胃炎、胃酸过多、胃灼热、腹胀、消化不良及痉挛；
2.预防因非甾体抗炎药物由于抑制前列腺素合成而引起的严重胃肠道副作用（胃溃疡或胃炎），也可有效防御癌症患者因化疗药物对胃肠道黏膜细胞的破坏而引起的胃肠道副作用（胃肠道不适/出血/溃疡等）。
- Associated Conditions
- -
- Associated Therapies
- -
Lipid-lowering Effects of Gefarnate in Statin-treated Coronary Heart Disease Patients With Residual Hypertriglyceridemia
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2020-07-30
- Target Recruit Count
- 70
- Registration Number
- NCT03610321
- Locations
- 🇨🇳
the first affiliated hospital of Harbin medical university, Harbin, Heilongjiang, China
Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 366
- Registration Number
- NCT00787254
A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 461
- Registration Number
- NCT00762359
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath